Manufacturing Industry

PFIZER INC - Research Update.

PR Newswire UK Disclose, July, 2005

 
                 Phase 1/2a Study Results Indicate Maraviroc 
               Well-Tolerated In Doses Up To 300 mg Twice-Daily 
 
  Maraviroc Reduced Viral Load Significantly In Phase 2a Monotherapy Studies 
 
   Maraviroc Development Program Granted Fast Track Designation By U.S. FDA 
 
    RIO DE JANEIRO, Brazil, July 26 -- Results from early-stage clinical trials, 
presented today at the 3rd International AIDS Society Conference on Pathogenesis 
and Treatment, indicate that maraviroc, an investigational drug for treatment of 
HIV/AIDS, was well-tolerated and decreased patient levels of HIV significantly 
in 10-day monotherapy studies in asymptomatic HIV-positive patients. 
    Maraviroc works through a different mechanism of action from currently 
marketed drugs.  In a...

            
        
    
    	    
                
                
	
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
  • Click Here
advertisement